MCET (MultiCell Technologies) OCF Margin %: -40.51% (As of Aug. 2015)


What is MultiCell Technologies OCF Margin %?

MultiCell Technologies MCET -90.00% OCF Margin % is -40.51% as of Aug. 2015.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. MultiCell Technologies's Cash Flow from Operations for the three months ended in Aug. 2015 was $-0.08 Mil. MultiCell Technologies's Revenue for the three months ended in Aug. 2015 was $0.20 Mil. Therefore, MultiCell Technologies's OCF Margin % for the quarter that ended in Aug. 2015 was -40.51%.

As of today, MultiCell Technologies's current OCF Yield % is -5,989,100.00%.

The historical rank and industry rank for MultiCell Technologies's OCF Margin % or its related term are showing as below:

MCET' s OCF Margin % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: -24.47

MCET's OCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -64.23 vs MCET: -24.47

MultiCell Technologies OCF Margin % Related Terms

MultiCell Technologies OCF Margin % Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies OCF Margin % Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -755.56 -2,528.57 -1,816.33 -2,553.06 -2,220.41

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,783.33 -2,491.67 -1,050.00 52.39 -40.51

MCET vs ERGO, OPLI, GLAG: OCF Margin % Comparison

For the Biotechnology subindustry, MultiCell Technologies's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MultiCell Technologies OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's OCF Margin % distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's OCF Margin % falls into.


MultiCell Technologies OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

MultiCell Technologies's OCF Margin for the fiscal year that ended in Nov. 2014 is calculated as

OCF Margin=Cash Flow from Operations (A: Nov. 2014 )/Revenue (A: Nov. 2014 )
=-1.088/0.049
=-2,220.41 %

MultiCell Technologies's OCF Margin for the quarter that ended in Aug. 2015 is calculated as

OCF Margin=Cash Flow from Operations (Q: Aug. 2015 )/Revenue (Q: Aug. 2015 )
=-0.079/0.195
=-40.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -40.51% mean?
MultiCell Technologies (MCET) has a OCF Margin % of -40.51% as of Aug. 2015. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on MultiCell Technologies and its competitors.
Is MultiCell Technologies' OCF Margin % too high?
MultiCell Technologies' current OCF Margin % is -40.51%.
How does MultiCell Technologies' OCF Margin % compare to ERGO and OPLI?
MultiCell Technologies' OCF Margin % of -40.51% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on MultiCell Technologies and its competitors. MultiCell Technologies's current OCF Margin % is -40.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current OCF Margin % of -40.51%. The current OCF Margin % is -40.51%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current OCF Margin % is -40.51% as of Aug. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.